Suche

A smartphone-guided health app reduces systolic blood pressure in patients with uncontrolled hypertension: Findings from the HELP Study

https://doi.org/10.1007/s00392-025-02625-4

Andreas Zietzer (Bonn)1, P. Düsing (Bonn)1, F. Brokamp (Otterberg)2, S. Schäfer (Köln)3, U. Stieber (Duisburg)4, K. Wilhelm (Dachau)5, D. Zgouras (Aschaffenburg)6, S. H. Schirmer (Kaiserslautern)7

1Universitätsklinikum Bonn Medizinische Klinik und Poliklinik II Bonn, Deutschland; 2Hausärztliche Praxis Brokamp und Kollegen Otterberg, Deutschland; 3Praxis Rheingalerie Gemeinschaftspraxis für Innere Medizin und Kardiologie Köln, Deutschland; 4Kardiopraxis Rote Straße Duisburg, Deutschland; 5Medizinisches Versorgungszentrum Dachau Dachau, Deutschland; 6Strietwaldpraxis Aschaffenburg, Deutschland; 7Kardiopraxis Schirmer‍ Kaiserslautern, Deutschland

 

 
 
 
 
 
 
 
 
Background
Hypertension is a major risk factor for cardiovascular diseases and is linked to kidney disease, retinal disease, and stroke. Current guidelines recommend a combination of medication and lifestyle changes, including diet, exercise, blood pressure monitoring, and medication adherence. The Vantis | Bluthochdruck (Vantis app) was developed to support patients and physicians in these Areas. It’s effectiveness is tested in the HELP study.
 
Methods 
The HELP study was a prospective, randomized, controlled, multicenter trial conducted across seven German centers to evaluate whether the Vantis app could reduce systolic blood pressure (SBP) in patients with uncontrolled hypertension. Ninety-eight hypertensive patients were randomly assigned to either an intervention group (using the Vantis app) or a control group. After 13 weeks, changes in SBP were measured as the primary endpoint, while secondary endpoints included diastolic blood pressure, resting heart rate, BMI, and adherence to therapy.
 
Results  
The main analysis followed an intention-to-treat approach. The intervention group showed a significant reduction in SBP, averaging a 12.7 ± 2.0 mmHg decrease (p < 0.001). The difference between the intervention and control groups was also statistically significant, with a mean SBP difference of 5.5 ± 2.1 mmHg (p = 0.011). Patients using the app exhibited improved therapy adherence and more frequent blood pressure monitoring. However, there were no significant differences between groups in diastolic blood pressure, heart rate, or BMI. No adverse events related to the app were reported.
 
Conclusion 
The HELP study demonstrates that the Vantis app effectively reduces systolic blood pressure and improves guideline adherence in patients with uncontrolled hypertension, suggesting it as a novel and innovative tool in hypertension management.
Diese Seite teilen